These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 36640905)

  • 1. Genetically engineered human pituitary corticotroph tumor organoids exhibit divergent responses to glucocorticoid receptor modulators.
    Mallick S; Chakrabarti J; Eschbacher J; Moraitis AG; Greenstein AE; Churko J; Pond KW; Livolsi A; Thorne CA; Little AS; Yuen KCJ; Zavros Y
    Transl Res; 2023 Jun; 256():56-72. PubMed ID: 36640905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant.
    Pivonello R; Munster PN; Terzolo M; Ferrigno R; Simeoli C; Puglisi S; Bali U; Moraitis AG
    Front Endocrinol (Lausanne); 2021; 12():793262. PubMed ID: 35058882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing's disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone.
    Fleseriu M; Findling JW; Koch CA; Schlaffer SM; Buchfelder M; Gross C
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3718-27. PubMed ID: 25013998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo.
    Murasawa S; Kageyama K; Sugiyama A; Ishigame N; Niioka K; Suda T; Daimon M
    Mol Cell Endocrinol; 2014 Aug; 394(1-2):37-46. PubMed ID: 25011056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The expression of glucocorticoid and mineralocorticoid receptors in pituitary tumors causing Cushing's disease and silent corticotroph tumors.
    Kober P; Rusetska N; Mossakowska BJ; Maksymowicz M; Pękul M; Zieliński G; Styk A; Kunicki J; Działach Ł; Witek P; Bujko M
    Front Endocrinol (Lausanne); 2023; 14():1124646. PubMed ID: 37065760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral glucocorticoid receptor antagonism by relacorilant with modest HPA axis disinhibition.
    Viho EMG; Kroon J; Feelders RA; Houtman R; van den Dungen ESR; Pereira AM; Hunt HJ; Hofland LJ; Meijer OC
    J Endocrinol; 2023 Feb; 256(2):. PubMed ID: 36445262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. USP8 inhibitor RA-9 reduces ACTH release and cell growth in tumor corticotrophs.
    Treppiedi D; Di Muro G; Marra G; Barbieri AM; Mangili F; Catalano R; Serban A; Ferrante E; Locatelli M; Lania AG; Arosio M; Spada A; Peverelli E; Mantovani G
    Endocr Relat Cancer; 2021 Jun; 28(8):573-582. PubMed ID: 34086599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relevance of mutations in protein deubiquitinases genes and
    Pękul M; Szczepaniak M; Kober P; Rusetska N; Mossakowska BJ; Baluszek S; Kowalik A; Maksymowicz M; Zieliński G; Kunicki J; Witek P; Bujko M
    Front Endocrinol (Lausanne); 2024; 15():1302667. PubMed ID: 38487343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of Human Pituitary Neuroendocrine Tumor Organoids to Facilitate Effective Targeted Treatments of Cushing's Disease.
    Chakrabarti J; Pandey R; Churko JM; Eschbacher J; Mallick S; Chen Y; Hermes B; Mallick P; Stansfield BN; Pond KW; Thorne CA; Yuen KCJ; Little AS; Zavros Y
    Cells; 2022 Oct; 11(21):. PubMed ID: 36359740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Glucocorticoid Receptor in the Pathophysiology of Pituitary Corticotroph Adenomas.
    Regazzo D; Mondin A; Scaroni C; Occhi G; Barbot M
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved pasireotide response in USP8 mutant corticotroph tumours in vitro.
    Albani A; Perez-Rivas LG; Tang S; Simon J; Lucia KE; Colón-Bolea P; Schopohl J; Roeber S; Buchfelder M; Rotermund R; Flitsch J; Thorsteinsdottir J; Herms J; Stalla G; Reincke M; Theodoropoulou M
    Endocr Relat Cancer; 2022 Aug; 29(8):503-511. PubMed ID: 35686696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of somatostatin analogs in Cushing's disease.
    van der Hoek J; Lamberts SW; Hofland LJ
    Pituitary; 2004; 7(4):257-64. PubMed ID: 16132202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pasireotide and mifepristone: new options in the medical management of Cushing's disease.
    Cohan P
    Endocr Pract; 2014 Jan; 20(1):84-93. PubMed ID: 24126229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin suppresses growth and adrenocorticotrophic hormone secretion in mouse pituitary corticotroph tumor AtT20 cells.
    Jin K; Ruan L; Pu J; Zhong A; Wang F; Tan S; Huang H; Mu J; Yang G
    Mol Cell Endocrinol; 2018 Dec; 478():53-61. PubMed ID: 30025915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy.
    Ben-Shlomo A; Schmid H; Wawrowsky K; Pichurin O; Hubina E; Chesnokova V; Liu NA; Culler M; Melmed S
    J Clin Endocrinol Metab; 2009 Nov; 94(11):4342-50. PubMed ID: 19820006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanisms involved in somatostatin receptor regulation in corticotroph tumors: the role of cytoskeleton and USP8 mutations.
    Peverelli E; Treppiedi D; Mantovani G
    Endocr Oncol; 2022 Jan; 2(1):R24-R30. PubMed ID: 37435448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New avenues in the medical treatment of Cushing's disease: corticotroph tumor targeted therapy.
    Fleseriu M; Petersenn S
    J Neurooncol; 2013 Aug; 114(1):1-11. PubMed ID: 23673515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein kinase C delta mediates Pasireotide effects in an ACTH-secreting pituitary tumor cell line.
    Gentilin E; Borges De Souza P; Ambrosio MR; Bondanelli M; Gagliardi I; Zatelli MC
    J Endocrinol Invest; 2023 Dec; 46(12):2609-2616. PubMed ID: 37233978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Spectrum of USP8 Pathogenic Variants in Cushing's Disease.
    Rebollar-Vega RG; Zuarth-Vázquez JM; Hernández-Ramírez LC
    Arch Med Res; 2023 Dec; 54(8):102899. PubMed ID: 37925320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas.
    Tateno T; Kato M; Tani Y; Oyama K; Yamada S; Hirata Y
    Endocr J; 2009; 56(4):579-84. PubMed ID: 19318729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.